Targeting Microenvironment-Mediated NFIob Activation With MLN4924, An Inhibitor Of The Nedd8-Activating Enzyme, In Chronic Lymphocytic Leukemia B Cells »
04/06/14

p53 Pathway Alterations Influence Survival and Treatment Response In Chronic Lymphocytic Leukemia »
04/06/14

Anti-Tumour Efficacy Study Of The Brutona€™s Tyrosine Kinase (Btk) Inhibitor, ONO-4059, In Combination With The Glycoengineered Type II Anti-CD20 Monoclonal Antibody, Obinutuzumab (GA101) Demonstrates Superior In Vivo Efficacy Compared To ONO-4059 In Combination With Rituximab »
04/06/14

Incidence Rate Of Venous Thromboembolism (VTE) and Utilization Of a VTE Prophylaxis Order Set Module In Hospitalized Patients With Leukemia »
04/06/14

How Many Life Years Have Been Saved In The United States From Using Rituximab Plus Chemotherapy Compared To Chemotherapy Alone From 1998-2013 »
04/06/14

Assessment Of Hypersensitivity Reactions and Feasibility Of a 60 Minute Rapid Infusion Rituximab Protocol At a Comprehensive Cancer Center »
04/06/14

Head-To-Head Comparison Of Obinutuzumab (GA101) Plus Chlorambucil (Clb) Versus Rituximab Plus Clb In Patients With Chronic Lymphocytic Leukemia (CLL) and Co-Existing Medical Conditions (Comorbidities): Final Stage 2 Results Of The CLL11 Trial »
04/06/14

Living In Remission: Disparities In Conditional Survival Among Non-Hodgkin Lymphoma Survivors »
04/06/14

Interrogation Of Signaling Networks In B Cell Malignancies To Improve Classification Of Patient Subsets For Targeted Therapy »
04/06/14

BMS-936564 (Anti-CXCR4 Antibody) Induces Specific »
04/07/14